Skip to main content

Robert J. Bitterman, Sr.

Robert Bitterman Sr. is the founder and CEO at Cutanea Life Sciences.

Robert J. Bitterman, Sr.

President and Chief Executive Officer

Robert Bitterman founded Cutanea Life Sciences Inc. in September 2005 as its President, Chief Executive Officer, and Board Director. Mr. Bitterman has had an extensive and successful career in the pharmaceutical industry achieving various milestones, most notably, the sale of Cutanea to Maruho Company Ltd. in February 2012. Maruho is a privately owned Japanese dermatology-focused pharmaceutical company which celebrated its 100th year anniversary in October of 2015. During his tenure he has successfully transacted two proprietary technology license agreements in addition to acquiring a third technology and a commercially ready to market product. These form the foundation of Cutanea’s development and commercial operations for future value creation.

Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 into 2004. Under his direction Dermik secured FDA approval for six NDA’s (New Product Approvals) and one PMA, a class 3 medical device. He also directed eight commercial product launches in the U.S. and several product launches in other international markets. Mr. Bitterman was also responsible for constructing and directing an operating joint venture in the People’s Republic of China. During his ten year tenure at Dermik Laboratories he led his team in achieving average sales and EBITA growth of 21% and 24%, respectively. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc. from September 2004 until April 2005.

Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine and is a member of the Philadelphia Business Leaders Network.

He also serves as a director on the Board of Directors of Rxi Pharmaceutical Corporation.